Brief: Alteogen receives patent
13/10/2017 05:14
Oct 13 (Reuters) - Alteogen Inc 196170.KQ :
* Says it receives patent named modified antibody in which
motif comprising cysteine residue is bound, modified
antibody-drug conjugate comprising the modified antibody, and
production
Source text in Korean: https://goo.gl/PpQwrz
Further company coverage: 196170.KQ
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; Reuters Messaging:
Yinglan.Ma@thomsonreuters.com@reuters.net))
Recent news on Alteogen
See all newsBrief: Alteogen Enters Into A License Agreement With Biogen For Development And Commercialization Of Hybrozyme™-Based Subcutaneous Biologics
Brief: Alteogen Signs Licensing Deal With Biogen International For Alt-B4
Brief: Alteogen 2025 Operating Profit 115 Billion Won, Up 275% From Year Earlier
Brief: Alteogen Signs $285 Million Contract With Gsk Unit
Brief: Alteogen Receives Positive CHMP Opinion For Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'